Stockreport

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

ACADIA Pharmaceuticals Inc.  (ACAD) 
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm Check Earnings Report
PDF -- Study supported FDA and Health Canada approvals of DAYBUE for treatment of Rett syndrome in patients ages two years and older-- Results consistent with Phase 3 LAVEND [Read more]